Specifically, the NOX2/4 inhibitor VAS2870 [169] was found to reduce platelet aggregation and delay thrombus formation via the PKC signaling pathway in experimental rodent models, while normal hemostasis was not affected by VAS2870 [170, 171], suggesting VAS2870 may be a potentially safe and effective agent for stroke-related thrombosis prevention. This evidence concerns the gene CYBB and stroke disorder.